RVPH
Reviva Pharmaceuticals Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.56
+2.78%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 1394.6B | 11.7M | 22.9M | 31.4M | 18.9M |
| SG&A Expense | 1223.0B | 8.5M | 7.9M | 8.1M | 5.4M |
| General & Admin Expense | 1223.0B | 8.5M | 7.9M | 8.1M | 5.4M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 2617.6B | 20.2M | 30.8M | 39.5M | 24.3M |
| Cost and Expenses | 10.9M | 20.2M | (30.8M) | 39.5M | 24.3M |
| Operating Income (EBIT) | (2617.6B) | (20.2M) | (30.8M) | (39.5M) | (24.3M) |
| Non-Operating | |||||
| Interest Income | 176.3B | 311.4K | 361.4K | 398.4K | 182.8K |
| Interest Expense | (2.9B) | 13.4K | 18.5K | 33.7K | 182.8K |
| Net Interest Income | 282.5K | 298.0K | 342.9K | 364.7K | 182.8K |
| Other Non-Op Income/Expense | 172.3B | 354.0K | 899.6K | 259.7K | (11.9K) |
| Non-Operating Income (excl Interest) | (292.4K) | (367.4K) | (918.1K) | (259.7K) | — |
| EBT (Pre-Tax Income) | (2445.2B) | (19.8M) | (29.9M) | (39.2M) | (24.3M) |
| Income Tax Expense | 2.6B | 18.9K | 19.5K | 16.9K | 20.8K |
| Bottom Line | |||||
| Net Income | (2447.8B) | (19.9M) | (29.9M) | (39.3M) | (24.3M) |
| Earnings from Cont. Ops | (2447.8B) | (19.9M) | (29.9M) | (39.3M) | (24.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (2447.8B) | (19.9M) | (29.9M) | (39.3M) | (28.3M) |
| Per Share | |||||
| Basic EPS | ($6.96) | ($5.48) | ($18.00) | ($33.00) | ($29.00) |
| Diluted EPS | ($6.96) | ($5.48) | ($18.00) | ($33.00) | ($29.00) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 13.2M | 3.6M | 1.7M | 1.2M | 975824 |
| Diluted Shares Outstanding | 13.2M | 3.6M | 1.7M | 1.2M | 975824 |
| Profitability Metrics | |||||
| EBITDA | (2617.6B) | (19.8M) | (29.9M) | (39.2M) | (24.1M) |
| D&A | — | — | 30.8M | 39.5M | 194.7K |
| EBIT | (10.6M) | (19.8M) | (29.9M) | (39.2M) | (24.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026